First-line medication dosing in pediatric refractory status epilepticus.
Alejandra VasquezMarina Gaínza-LeinNicholas S AbendMarta Amengual-GualAnne AndersonRavindra AryaJames Nicholas BrentonJessica L CarpenterKevin ChapmanJustice ClarkRaquel Farias-MoellerWilliam D GaillardTracy GlauserJoshua L GoldsteinHoward P GoodkinRejean M GuerrieroKush KapurYi-Chen LaiTiffani L McDonoughMohamad A MikatiLindsey A MorganEdward J NovotnyAdam P OstendorfEric T PayneKatrina PearisoJuan PiantinoJames J RivielloKumar SannagowdaraRobert Charles TaskerDmitry TchapyjnikovAlexis TopjianMark S WainwrightAngus WilfongKorwyn WilliamsTobias Loddenkempernull nullPublished in: Neurology (2020)
This study provides Class III evidence that patients with RSE who present with male sex, older age, no prior diagnosis of epilepsy, and delayed BZD treatment are more likely to receive low total BZD doses. This study provides Class III evidence that in pediatric RSE low total BZD dose decreases the likelihood of seizure cessation.